50
Participants
Start Date
January 14, 2023
Primary Completion Date
December 31, 2026
Study Completion Date
December 31, 2027
Ibudilast
IBUD at a dosage of 20 mg twice daily for 2 days, with an increase to 50 mg twice daily on day 3. The dosage will remain at 50 mg twice daily through most of the rest of the 6-week treatment period. However, for the last three days of week 6, participants will reduce the dosage gradually to 20 mg twice daily prior to discontinuing it at the end of the treatment period.
Medical management
All subjects receive 6 weeks of medical management (Pettinati et al. 2004) will support subjects efforts to reduce or stop their drinking.
Placebo
Placebo twice daily for 6-week treatment period. Placebo will match active medication in appearance and size.
University of Pennsylvania Center for Studies of Addiction, Philadelphia
University of Pennsylvania
OTHER